Trade Filana Therapeutics Inc - FLNA CFD

Trading Conditions

• TypeThis financial market is available for CFD trading.Learn more about:CFDs: CFD
• Spread: 0.05
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.021568 %(-$4.31)Trade size with leverage ~ $20,000.00Money from leverage ~ $$19,000.00Go to platform: -0.02157%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.000654 %(-$0.13)Trade size with leverage ~ $20,000.00Money from leverage ~ $$19,000.00Go to platform: -0.00065%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 10
• Margin: 5.00%
• Stock exchange: United States of America
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.021568 %
  (-$4.31)

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.000654 %
  (-$0.13)

Key Stats

• Prev. Close: 0.92
• Open: 0.92
• 1-Year Change: -59.47%
• Day's Range: 0.92 - 0.99

Trade Filana Therapeutics Inc - FLNA

Cassava Science Inc is a clinical-stage biopharmaceutical company that specialises in detecting and treating Alzheimer’s disease, an incurable progressive neurologic disorder, which is . The company is listed on the Nasdaq under the ticker SAVA.

According to Cassava, over five million people in the US have Alzheimer’s. The company focuses on research and development to find new approaches for its treatment and diagnosis. 

Cassava is developing Simufilam for the proposed treatment of Alzheimer's. According to the company, Simufilam is a proprietary oral drug candidate, developed in-house with academic collaborators. Simufilam, or PTI-125, is the company’s lead therapeutic product candidate. It’s currently (17 March) undergoing Phase 3 clinical studies.

SavaDx is the company’s investigational diagnostic for Alzheimer’s. According to the company, SavaDx is being developed to detect the disease with a simple blood test. However, SavaDx is still an early-stage product candidate and a lower priority than Simufilam, Cassava said.

Cassava was incorporated in 1998. It’s based in Austin, Texas, US. Remi Barbier has served as president, CEO and chairman of the board of directors since the company’s inception. Nadav Friedmann is the company’s chief medical officer. James Kupiec is the chief clinical development officer.